{
    "organizations": [],
    "uuid": "16dfca5c940fccbae134a966f908dda94a292aeb",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/idUSL8N1S90PC",
    "ord_in_thread": 0,
    "title": "BRIEF-Noxxon Pharma Says Will Need Significant Additional Funds To Conduct Its Future Clinical Trials",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 2 (Reuters) - NOXXON PHARMA:\n* ANNOUNCED ON MONDAY THAT ITS FY REVENUE WAS € NIL FOR 2017 COMPARED TO € 83 THOUSAND FOR 2016\n* FY LOSS FROM OPERATIONS 4.7 MILLION EUROS VS LOSS 8.6 MILLION EUROS\n* NET LOSS – ATTRIBUTABLE TO OWNERS OF CO 5.4 MILLION EUROS VS LOSS 10.7 MILLION EUROS\n* SAYS TO CONDUCT ALL CLINICAL TRIALS THAT IT WOULD LIKE TO EXECUTE IN COMING THREE YEARS, WILL NEED SIGNIFICANT ADDITIONAL FUNDS\n* SAYS MANAGEMENT IS PURSUING VARIOUS FINANCING ALTERNATIVES TO MEET THE GROUP’S FUTURE CASH REQUIREMENTS\n* SAYS ALTERNATIVES INCLUDE SEEKING ADDITIONAL INVESTORS, PURSUING INDUSTRIAL PARTNERSHIPS, OR OBTAINING FURTHER FUNDING FROM EXISTING INVESTORS THROUGH ADDITIONAL FUNDING ROUNDS, PURSUING MERGER OR ACQUISITION\n* BASED ON OPTIONS AVAILABLE, MANAGEMENT IS CONFIDENT TO BE ABLE TO RAISE ADDITIONAL CAPITAL, PREFERABLY IN FORM OF EQUITY\n* NO FINANCING COMMITMENTS WERE RECEIVED BY THE COMPANY AS OF TODAY\nSource text: bit.ly/2w2aPLp\nFurther company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-05-02T14:00:00.000+03:00",
    "crawled": "2018-05-03T12:20:33.023+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "noxxon",
        "pharma",
        "announced",
        "monday",
        "fy",
        "revenue",
        "nil",
        "compared",
        "thousand",
        "fy",
        "loss",
        "operation",
        "million",
        "euro",
        "v",
        "loss",
        "million",
        "euro",
        "net",
        "loss",
        "attributable",
        "owner",
        "co",
        "million",
        "euro",
        "v",
        "loss",
        "million",
        "euro",
        "say",
        "conduct",
        "clinical",
        "trial",
        "would",
        "like",
        "execute",
        "coming",
        "three",
        "year",
        "need",
        "significant",
        "additional",
        "fund",
        "say",
        "management",
        "pursuing",
        "various",
        "financing",
        "alternative",
        "meet",
        "group",
        "future",
        "cash",
        "requirement",
        "say",
        "alternative",
        "include",
        "seeking",
        "additional",
        "investor",
        "pursuing",
        "industrial",
        "partnership",
        "obtaining",
        "funding",
        "existing",
        "investor",
        "additional",
        "funding",
        "round",
        "pursuing",
        "merger",
        "acquisition",
        "based",
        "option",
        "available",
        "management",
        "confident",
        "able",
        "raise",
        "additional",
        "capital",
        "preferably",
        "form",
        "equity",
        "financing",
        "commitment",
        "received",
        "company",
        "today",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}